MindMed Files 8-K for Material Definitive Agreement

TL;DR

MindMed signed a big deal on 5/28, filing an 8-K. Details to follow.

AI Summary

On May 28, 2024, Mind Medicine (MindMed) Inc. entered into a material definitive agreement. The company, incorporated in British Columbia, Canada, filed an 8-K report detailing this event. The filing also includes financial statements and exhibits.

Why It Matters

This filing indicates a significant business development for MindMed, potentially impacting its operations, partnerships, or financial structure.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.

Key Players & Entities

• Mind Medicine (MindMed) Inc. (company) — Registrant
• May 28, 2024 (date) — Date of earliest event reported
• 212-220-6633 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $150,000,000 — m time to time may offer and sell up to $150,000,000 of common shares, no par value per shar

Filing Documents

• tm2416299d1_8k.htm (8-K) — 30KB
• 0001104659-24-076037.txt ( ) — 201KB
• mnmd-20240528.xsd (EX-101.SCH) — 3KB
• mnmd-20240528_lab.xml (EX-101.LAB) — 33KB
• mnmd-20240528_pre.xml (EX-101.PRE) — 22KB
• tm2416299d1_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On June 28, 2024, Mind Medicine (MindMed) Inc. (the "Company") entered into a Sales Agreement (the "Agreement") with Leerink Partners LLC (the "Agent") to create an "at-the-market" equity program under which the Company from time to time may offer and sell up to $150,000,000 of common shares, no par value per share, of the Company (the "ATM Shares"), through or to the Agent. use its commercially reasonable efforts to sell the ATM Shares from time to time, based upon the Company's instructions. The Company has provided the Agent with customary indemnification rights, and the Agent will be entitled to a commission of up to 3.0% of the aggregate gross proceeds from each sale of the ATM Shares effectuated through or to the Agent. Sales of the ATM Shares, if any, under the Agreement may be made in transactions that are deemed to be "at the market offerings" as defined in Rule 415 under the Securities Act of 1933, as amended. The Company has no obligation to sell any of the ATM Shares and may at any time suspend offers under the Agreement or terminate the Agreement. This foregoing description of the terms of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated into this Item 1.01 by reference. The Agreement was entered into in connection with the Company's filing of an automatic shelf registration Statement on Form S-3 (File No. 333-280548) with the U.S. Securities and Exchange Commission, which includes a prospectus supplement covering the offering, issuance and sale by the Company of the ATM Shares that may be issued and sold under the Agreement. This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any common shares, no par value per

01 Other Events

Item 8.01 Other Events. On May 28, 2024, the Company delivered written notice to Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. (the "Prior Agents") that it was terminating the Controlled Equity Offering SM Sales Agreement, dated as of May 3, 2022, by and among the Company and the Prior Agents.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Sales Agreement, dated as of June 28, 2024, by and between Mind Medicine (MindMed) Inc. and Leerink Partners LLC (incorporated by reference to Exhibit 1.2 of the Form S-3 Registration Statement filed on June 28, 2024) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIND MEDICINE (MINDMED) INC. Date: June 28, 2024 By: /s/ Robert Barrow Name: Robert Barrow Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR